Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma.

ABSTRACT: CALGB (Alliance) 100001 was a phase II study evaluating autologous stem cell transplant (ASCT) followed by nonmyeloablative allogeneic stem cell transplant (alloSCT) in patients with multiple myeloma who had received no more than 18 months of prior therapy and had experienced no more than 1 prior progression event. Conditioning for ASCT was with high-dose melphalan (200 mg/m²). The alloSCT reduced-intensity conditioning (RIC) regimen consisted of fludarabine (30 mg/m²/d i.v. on days -7 through -3) and cyclophosphamide (1 g/m²/d i.v. on days -4 through -3). The primary objective was to determine the 6-month post-alloSCT treatment-related mortality (TRM) rate. Additional objectives included determining the proportion of patients who could complete this tandem

SUBMITTER: Holstein SA 

PROVIDER: S-EPMC7371544 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature